Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment.
Sep 25, 2026
Contract Type
partnership
CambridgeBiotechnologySoftwareHealth CareScience And Engineering
Description
Roche has made a significant investment by paying Atavistik Bio USD 70 million upfront as part of a research partnership. This partnership aims to advance innovative drug discovery efforts.
Quick answer
Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment. (September 25, 2026). Atavistik Bio is based in Cambridge, Massachusetts, United States.
What agreement did Atavistik Bio announce on September 25, 2026?
Roche has made a significant investment by paying Atavistik Bio USD 70 million upfront as part of a research partnership. This partnership aims to advance innovative drug discovery efforts.
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
Where is Atavistik Bio based?
Atavistik Bio is based in Cambridge, Massachusetts, United States.
Source: Fundz verified event record.
Company Information
Company
Atavistik Bio
Location
Cambridge, Massachusetts, United States
About
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.